Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nurabio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of transformative medicines for debilitating neurodegenerative diseases. Their core scientific approach centers on targeting SARM1, a protein central to promoting axonal degeneration, a common pathological feature in a wide range of neurological disorders including Parkinson's disease, Alzheimer's disease, ALS, and peripheral neuropathies. By developing potent SARM1 inhibitors, Nurabio aims to prevent neuronal damage, thereby slowing or halting disease progression and significantly improving patient outcomes.
The headquarters serves as the primary center for Nurabio's research and development activities, clinical operations, strategic decision-making, and corporate administration.
Located within a specialized life sciences campus, providing access to advanced laboratory facilities and fostering collaboration within the dense biotech ecosystem of the Bay Area.
Nurabio likely cultivates a science-driven, innovative, and collaborative work environment. Employees are typically mission-oriented, focused on rigorous research and the potential to make a significant impact on patients with neurodegenerative diseases.
Its location in South San Francisco offers strategic advantages, including access to a highly skilled talent pool, proximity to leading academic research institutions, and opportunities for partnerships with other biotech and pharmaceutical companies.
While Nurabio's physical headquarters and primary operations are based in the United States, its scientific collaborations, clinical trial activities, and future commercialization efforts are likely to have a global scope. The company engages with the international scientific community, participates in global conferences, and plans to seek regulatory approvals in multiple regions to make its therapies available to patients worldwide.
201 Haskins Way, Suite 216
South San Francisco
CA
USA
Address: N/A
The company's focus is on leveraging its main R&D and corporate hub for its current stage of development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nura Bio' leadership includes:
Nura Bio has been backed by several prominent investors over the years, including:
Nurabio significantly bolstered its clinical leadership in the past year with the appointment of a new Chief Medical Officer. No major executive departures were publicly announced during this period.
Discover the tools Nura Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for companies like Nurabio include combinations of first name, last name, and initials. While the precise format isn't publicly confirmed, a likely pattern is [firstinitial][lastname]@nurabio.com. For official contact, it's recommended to use the contact information or forms available on the company's website.
[firstinitial][last]@nurabio.com
Format
aseth@nurabio.com (example for Alpna Seth)
Example
75%
Success rate
Nurabio Website / Press Release • November 13, 2023
Nurabio shared promising preclinical findings for its SARM1 inhibitor program, featuring its lead candidate NB-509. The data, presented at the SfN 2023 annual meeting, highlighted the potential of SARM1 inhibition in treating various neurodegenerative diseases by preventing axonal degeneration....more
Business Wire • June 12, 2023
Nurabio announced the strategic appointment of David S. Bredt, M.D., Ph.D., as its Chief Medical Officer. Dr. Bredt's extensive background in neuroscience and clinical development is expected to significantly contribute to advancing Nurabio's pipeline....more
Business Wire • April 12, 2023
Nurabio presented compelling preclinical data on its lead SARM1 inhibitor program at the American Academy of Neurology (AAN) 2023 Annual Meeting. The findings demonstrated the therapeutic potential of their approach for various neurological disorders characterized by axonal degeneration....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nura Bio, are just a search away.